In recent years, along with the development of various interventional techniques for malignant tumors such as chimeric antigen receptor (CAR)-based immunotherapy (Pouliliou et al., 2020; Ou et al., 2022), programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors treatment (Sun et al., 2021; Liu et al., 2021); molecular targeted therapy (Sheahan et al., 2018), monoclonal antibodies (Kho and Brouwers, 2012), etc. many scholars have also conducted bibliometric studies to make a comprehensive analysis of these novel therapeutic strategies. This evidence concerns the gene PDCD1 and cancer.